| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T459 |
0-61 |
Sentence |
denotes |
7 Cardiovascular benefits of n-3 polyunsaturated fatty acids |
| T460 |
62-371 |
Sentence |
denotes |
N-3 PUFAs and many of the their endogenously generated metabolites act as bioactive lipid molecules with a wide array of properties against numerous disorders including CVD (Lordan, Redfern, Tsoupras, & Zabetakis, 2020; Lordan, Tsoupras, & Zabetakis, 2017; Moro, Nagahashi, Ramanathan, Takabe, & Wakai, 2016). |
| T461 |
372-655 |
Sentence |
denotes |
Numerous studies have suggested higher consumption of n-3 PUFAs lowers the number of mortalities related to CVD (Darwesh, Sosnowski, Lee, Keshavarz-Bahaghighat, & Seubert, 2019; Kris-Etherton, Harris, Appel, & Nutrition, 2003; Lee, O'Keefe, Lavie, & Harris, 2009; Mozaffarian, 2007). |
| T462 |
656-922 |
Sentence |
denotes |
For instance, Mozaffarian et al. demonstrated higher plasma levels of n-3 PUFA biomarkers in a U.S. adults cohort study was associated with lower total mortality attributable with fewer cardiovascular compared to non-cardiovascular deaths (Mozaffarian et al., 2013). |
| T463 |
923-1285 |
Sentence |
denotes |
Currently, the intake of n-3 PUFAs is still recommended by the American Heart Association to prevent clinical CVD episodes in individuals with predominant coronary heart disease, such as a recent MI, to reduce death rates as well as individuals with prevalent HF to reduce hospitalizations and number of mortalities (Sacks et al., 2017; Siscovick, et al., 2017). |
| T464 |
1286-1431 |
Sentence |
denotes |
The cardiovascular benefits of n-3 PUFAs could be attributed to their pleiotropic effects on the different elements of the cardiovascular system. |
| T465 |
1432-1719 |
Sentence |
denotes |
Evidence suggests a higher intake of n-3 PUFAs has a beneficial effect on lipid profiles by replacing saturated fatty acids and lowering triglyceride levels, thereby stabilizing atherosclerotic plaques and reducing the incidence of thrombus formation (Plutzky, 1999; Thies et al., 2003). |
| T466 |
1720-2186 |
Sentence |
denotes |
Furthermore, n-3 PUFAs can enrich cell membranes and alter the lipid raft structure and function leading to improved organelle and cellular function (Din et al., 2008), autonomic tone (Abuissa, O'Keefe Jr., Harris, & Lavie, 2005; O'Keefe Jr., Abuissa, Sastre, Steinhaus, & Harris, 2006), elevated arrhythmic thresholds (Anand, Alkadri, Lavie, & Milani, 2008) and ameliorating hypertension (Geleijnse, Giltay, Grobbee, Donders, & Kok, 2002; O'Keefe Jr. et al., 2006). |
| T467 |
2187-2399 |
Sentence |
denotes |
Importantly, several experimental, clinical and epidemiological studies hypothesize that the cardioprotective effects of n-3 PUFAs and their metabolites are attributed mainly to their immunomodulatory properties. |
| T468 |
2400-2622 |
Sentence |
denotes |
Notably, emerging evidence demonstrates the ability of n-3 PUFAs to reduce circulating levels of inflammatory chemokines, cytokines, and the pro-inflammatory metabolites derived from n-6 PUFAs (Calder, 2013, Calder, 2017). |
